NCT03648788View on ClinicalTrials.gov

A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

September 30, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

August 31, 2024

Conditions
Mixed Dyslipidemia
Interventions
OTHER

NA (Observation study)

NA (Observation study)

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT03648788 - A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe | Biotech Hunter | Biotech Hunter